You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

REGADENOSON - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for regadenoson and what is the scope of patent protection?

Regadenoson is the generic ingredient in two branded drugs marketed by Astellas, Accord Hlthcare, Apotex, Baxter Hlthcare Corp, Dr Reddys, Eugia Pharma, Ge Healthcare, Gland Pharma Ltd, Hikma, Hospira, Ims Ltd, Indies Pharma, Meitheal, and Mylan, and is included in fourteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Regadenoson has twenty-eight patent family members in eighteen countries.

There are nine drug master file entries for regadenoson. Fifteen suppliers are listed for this compound.

Drug Prices for REGADENOSON

See drug prices for REGADENOSON

Recent Clinical Trials for REGADENOSON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
St. Jude Children's Research HospitalPhase 2
Emory UniversityN/A
Siemens Medical SolutionsN/A

See all REGADENOSON clinical trials

Pharmacology for REGADENOSON
Anatomical Therapeutic Chemical (ATC) Classes for REGADENOSON
Paragraph IV (Patent) Challenges for REGADENOSON
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LEXISCAN Injection regadenoson 0.08 mg/mL, 5 mL vial 022161 1 2012-04-10

US Patents and Regulatory Information for REGADENOSON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan REGADENOSON regadenoson SOLUTION;INTRAVENOUS 213856-001 Apr 4, 2023 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Meitheal REGADENOSON regadenoson SOLUTION;INTRAVENOUS 212806-001 Apr 11, 2022 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Apotex REGADENOSON regadenoson SOLUTION;INTRAVENOUS 207604-001 Apr 11, 2022 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for REGADENOSON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 ⤷  Subscribe ⤷  Subscribe
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 ⤷  Subscribe ⤷  Subscribe
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for REGADENOSON

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
GE Healthcare AS  Rapiscan regadenoson EMEA/H/C/001176
This medicinal product is for diagnostic use only.Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.
Authorised no no no 2010-09-06
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Supplementary Protection Certificates for REGADENOSON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1189916 11C0004 France ⤷  Subscribe PRODUCT NAME: REGADENOSON ET SES SELS; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
1189916 SPC/GB11/005 United Kingdom ⤷  Subscribe PRODUCT NAME: REGADENOSON; REGISTERED: UK EU/1/10/643/001 20100906
1189916 C300477 Netherlands ⤷  Subscribe PRODUCT NAME: REGADENOSON ALSMEDE FARMACEUTISCHE AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

REGADENOSON Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Regadenoson

Introduction

Regadenoson, marketed under the brand name Lexiscan, is a small molecule drug that has revolutionized the field of cardiovascular diagnostics, particularly in radionuclide myocardial perfusion imaging (MPI). Here, we delve into the market dynamics and financial trajectory of this significant pharmaceutical product.

Mechanism and Therapeutic Use

Regadenoson is an adenosine A2a receptor agonist, designed to dilate the arteries of the heart and increase blood flow. This action helps in identifying coronary artery disease, especially in patients who are unable to undergo adequate exercise stress[3][5].

Approval and Regulatory Milestones

Regadenoson was first approved by the FDA in April 2008 for use in the United States. This approval marked a significant milestone in the drug's journey, paving the way for its global market entry. The drug has since been approved in various countries for indications including coronary angiography and myocardial ischemia[2][3].

Market Share and Growth

Following its FDA approval, regadenoson saw a steady increase in market share. By November 2008, just a few months after its approval, the drug's market share had risen from 2% in July 2008 to 11%. This rapid growth underscores the drug's efficacy and the demand for pharmacologic stress agents in cardiovascular diagnostics[4].

Competitive Landscape

The market for pharmacologic stress agents is competitive, with regadenoson competing against other adenosine receptor agonists. However, its selective action on the A2a receptor and its proven safety profile have helped it maintain a strong position. The drug's ability to induce maximal hyperemia without the need for exercise stress has made it a preferred choice in many clinical settings[3][4].

Financial Performance

The financial performance of regadenoson has been robust, driven by its increasing adoption in clinical practice. According to market data, the sales of regadenoson have consistently grown since its approval. For instance, Amphastar Pharmaceuticals, which received FDA approval for its generic version of regadenoson in 2022, anticipates significant revenue from this product, given its market size and growth potential[1].

Pricing and Reimbursement

The pricing of regadenoson can vary based on the region and the specific formulation. However, it is generally priced competitively with other pharmacologic stress agents. Reimbursement policies also play a crucial role in the drug's financial trajectory. In many healthcare systems, regadenoson is covered under insurance plans, which helps in driving its adoption and revenue[5].

Clinical Trials and Research

Continuous research and clinical trials have been instrumental in expanding the therapeutic indications of regadenoson. Studies have explored its use in various cardiovascular conditions, including coronary artery disease, myocardial ischemia, and even in patients with chronic obstructive pulmonary disease (COPD) and asthma. These trials have not only enhanced the drug's safety profile but also opened up new market opportunities[2][4].

Side Effects and Safety Profile

While regadenoson is generally well-tolerated, it does come with some side effects, such as headache, dizziness, and increased heart rate. However, these side effects are typically transient and manageable. The safety profile of regadenoson has been extensively studied, and it has been found to be safe for use in a wide range of patients, including those with mild to moderate asthma and COPD[5].

Market Expansion and Global Reach

Regadenoson has achieved significant global reach since its approval. It is used in various countries for different indications related to cardiovascular health. The drug's global market presence is a testament to its therapeutic value and the demand for effective pharmacologic stress agents worldwide[2][3].

Future Outlook

The future outlook for regadenoson remains promising. With ongoing research and clinical trials, there is potential for expanding its therapeutic indications further. Additionally, the increasing prevalence of cardiovascular diseases globally is expected to drive the demand for diagnostic tools like regadenoson. As more generic versions enter the market, competition may increase, but the drug's established reputation and efficacy are likely to sustain its market position[1][3].

Key Takeaways

  • Mechanism and Use: Regadenoson is an adenosine A2a receptor agonist used for radionuclide myocardial perfusion imaging.
  • Approval and Growth: First approved in 2008, the drug has seen steady market share growth.
  • Financial Performance: Robust sales driven by clinical adoption and market demand.
  • Competitive Landscape: Strong position due to its selective action and safety profile.
  • Clinical Trials: Ongoing research expanding its therapeutic indications.
  • Safety Profile: Generally well-tolerated with manageable side effects.
  • Global Reach: Used in various countries for cardiovascular diagnostics.

FAQs

What is regadenoson used for?

Regadenoson is used as a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.

Who developed regadenoson?

Regadenoson was developed by Astellas Pharma, Inc.[3].

When was regadenoson first approved?

Regadenoson was first approved by the FDA in April 2008[2][3].

What are the common side effects of regadenoson?

Common side effects include headache, dizziness, and increased heart rate. Less common side effects include change in taste, loss of taste, and stomach soreness[5].

Is regadenoson safe for patients with respiratory conditions?

Regadenoson has been found to be safe for use in patients with mild to moderate asthma and chronic obstructive pulmonary disease (COPD)[5].

What is the market outlook for regadenoson?

The market outlook for regadenoson is promising, driven by increasing demand for cardiovascular diagnostics and ongoing research expanding its therapeutic indications.

Sources

  1. Amphastar Receives FDA Approval for Regadenoson - Accesswire
  2. Regadenoson - Synapse - Global Drug Intelligence Database - Synapse
  3. Regadenoson: Detailed Review of its Transformative R&D Success - Synapse
  4. Regadenoson: A New Myocardial Stress Agent - ScienceDirect
  5. Regadenoson (intravenous route) - Mayo Clinic

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.